Advertisement
Advertisement
U.S. markets close in 1 hour 13 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Stereotaxis, Inc. (STXS)

NYSE American - Nasdaq Real Time Price. Currency in USD
Add to watchlist
5.89+0.16 (+2.79%)
As of 2:43PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close5.73
Open5.71
Bid5.89 x 1100
Ask5.91 x 800
Day's Range5.77 - 6.00
52 Week Range3.03 - 10.30
Volume128,202
Avg. Volume358,178
Market Cap454.167M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)-0.10
Earnings DateNov 08, 2021 - Nov 12, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.40
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for STXS

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Stereotaxis, Inc.
    EW: Rating increased to a BUYEDWARDS LIFESCIENCES CORP has an Investment Rating of BUY; a target price of $116.000000; an Industry Subrating of High; a Management Subrating of High; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Medium.
    Rating
    Fair Value
    Economic Moat
    6 days agoArgus Research
View more
  • GlobeNewswire

    First Patients Treated in Southern Europe with Stereotaxis Genesis Robotic Technology

    ST. LOUIS, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced installation of its Genesis Robotic Magnetic Navigation (RMN) system at Princess Grace Hospital Center in Monaco, a leading center of research and training for the treatment of cardiac arrhythmias. Electrophysiologists at Princess Grace Hospital have been among the pioneers of robotic cardiac ablation in Europe, beco

  • GlobeNewswire

    International Journal of Cardiology Publishes Data Demonstrating Superior Outcomes of Stereotaxis Robotic Cardiac Ablation in Pediatric Patients

    ST. LOUIS, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced a publication in the International Journal of Cardiology: Heart & Vascular demonstrating superior safety and efficacy of Stereotaxis’ robotic technology to treat atrioventricular reentry tachycardia (AVRT) and atrioventricular nodal reentry tachycardia (AVNRT) in pediatric patients with heart rhythm disease. The 223-

  • GlobeNewswire

    Stereotaxis to Present at Upcoming Investor Conferences

    ST. LOUIS, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that David Fischel, Chairman and CEO, will present at two investor conferences in September 2021. Lake Street 5th Annual Best Ideas Growth ConferenceMr. Fischel will be available for one-on-one meetings on Wednesday, September 15, 2021. Cantor Virtual Global Healthcare ConferenceMr. Fischel will present an overview

Advertisement
Advertisement